352
T.E. 4 Esofagitis eosinofílicas. La visión de los pediatras alergólogos y gastroenterólogo
dren with eosinophilic esophagitis. J Pe-
diatr Gastroenterol Nutr. 2004; 38: 452-6.
60. Straumann A, Spichtin HP, Grize L, et al.
Natural history of primary eosinop- hilic
esophagitis: a follow-up of 30 adult pa-
tients for up to 11.5 years. Gastroentero
logy. 2003; 125: 1660-9.
61. Straumann A, Bussmann C, Zuber M, Van-
nini S, Simon HU, Schoepfer A. Eosin-oph-
ilic esophagitis: analysis of food impac-
tion and perforation in 251 adolescent and
adult patients. Clin Gastroenterol Hepatol
2008; 6:598-600.
Liacouras C. Reslizumab in children and
adolescents with eosinophilic esophagi-
tis: Results of a double-blind, randomized,
placebo-controlled trial. J. Allergy Clin Im-
munol 2012; 129:456-63.
58. Straumann A, Conus S, Grzonka P et al.
Anti-interleukin-5 antibody treatment (me-
polizumab) in active eosinophilic esopha-
gitis: a randomised, placebo controlled,
doble blind trial. Gut. 2010; 59(1) 21-30.
59. Sposito S, Marinello D, Paracchini R, et
al. Long-term follow-up of symptoms and
peripheral eosinophil counts in seven chil-
